Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Real-world Effectiveness of PD-(L)1 Inhibitors Alone or in Combination with Chemotherapy in First-line PDL1-high Non-squamous Lung Cancer

Name: Real-world Effectiveness of PD-(L)1 Inhibitors Alone or in Combination with Chemotherapy in First-line PDL1-high Non-squamous Lung Cancer
Start: 2021-04-08T16:30:00+00:00
End: 2021-04-09T11:45:00+00:00
Location: Real-world Effectiveness of PD-(L)1 Inhibitors Alone or in Combination with Chemotherapy in First-line PDL1-high Non-squamous Lung Cancer

ESMO-Virtual-Plenaries-April-2021-1000x250

Start date: 08 Apr 2021
End date: 09 Apr 2021

The ESMO Virtual Plenaries are freely available to all healthcare professionals working in Oncology.

Programme

Thursday 8 April

Welcome and introduction, Scientific background and context

Natasha Leighl, Princess Margaret Cancer Centre, Toronto, ON, Canada

Real world effectiveness of PD-(L)1 inhibitors alone or in combination with chemotherapy in first-line PDL1-high non-squamous lung cancer

Solange Peters, Centre Hospitalier Universitaire Vaudois – CHUV, Lausanne, Switzerland

Critical analysis and perspectives

Federico Cappuzzo, Istituto Nazionale Tumori Regina Elena, Rome, Italy

Live discussion and Q&A

Faculty and online audience (via chat feature)

Friday 9 April

Webcast of the ESMO Virtual Plenary plus additional live Discussion and Q&A with Faculty and online audience (via chat feature)